IP Library Granted Patent US 11,278,496
Granted Patent B2
US 11,278,496 · App. 16/371,262 · Granted Mar 22, 2022

Crystalline microspheres and the process of manufacturing the same

Inventors: Cecil W. Propst (Norton Shores, MI); Marc W. Meadows (Grand Haven, MI); Michael S. Todd (Grand Haven, MI)
Assignee: SPI Pharma, Inc.
A61K9/1623A61K9/16Y10T428/2982
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,278,496
App. No.
16/371,262
Granted
Mar 22, 2022
Kind
B2
Abstract

Microspheres comprising a core material, wherein the microspheres have a circularity greater than 0.95 and an aspect ratio greater than 0.95, and methods of manufacturing the same. The microspheres may be useful in the manufacture of sustained and modified release active pharmaceutical ingredient (API) microspheres, as a free flowing excipient for mini-tablets and in the manufacture of API dispersions.

Claims (20)

1. A microsphere comprising a core material that is crystalline, wherein the microsphere has a circularity greater than 0.98 and an aspect ratio greater than 0.98, wherein the microsphere has a surface with ridges of 10 um or less, and wherein the microsphere has a moisture gain of less than 0.5% at 90% relative humidity.

2. The microsphere of claim 1 , wherein the microsphere has a mean particle size from about 10 um to about 500 um.

3. The microsphere of claim 2 , wherein the microsphere has a mean particle size from about 10 um to about 20 um.

4. The microsphere of claim 1 , wherein the microsphere has a particle size distribution of 2.8 or less.

5. The microsphere of claim 4 , wherein the microsphere has a particle size distribution of 2.0 or less.

6. The microsphere of claim 4 , wherein the microsphere has a particle size distribution of 1.5 or less.

7. The microsphere of claim 4 , wherein the microsphere has a particle size distribution of 1.0.

8. The microsphere of claim 1 , wherein the microsphere has a skeletal density from about 1.4595 g/cc to about 1.4651 g/cc.

9. The microsphere of claim 1 , wherein the microsphere has a moisture content of 0.5% or less.

10. The microsphere of claim 1 , wherein the microsphere is water soluble.

11. The microsphere of claim 1 , wherein the microsphere comprises a single core material.

12. The microsphere of claim 11 , wherein the single core material is mannitol.

13. The microsphere of claim 1 , wherein the microsphere comprises a 100% crystalline core.

14. The microsphere of claim 1 , wherein the microsphere further comprises an active pharmaceutical ingredient.

15. The microsphere of claim 1 , wherein the core material is a polyol.

16. The microsphere of claim 15 , wherein the polyol is mannitol.

17. The microsphere of claim 1 , wherein the microsphere lacks internal voids.

18. The microsphere of claim 1 , wherein the microsphere has a moisture gain of less than 0.2% at 90% relative humidity.

19. A composition comprising the microsphere of claim 1 .

20. The composition of claim 19 , further comprising an active pharmaceutical ingredient.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 7, 2022
From: PROPST, CECIL W.; MEADOWS, MARC W.; TODD, MICHAEL S.
To: SPI PHARMA, INC.
Reel/Frame 058902/0195 →
Continuity (5)
Continuation 14809362 · Jul 27, 2015
Continuation 13870556 · Apr 25, 2013
Provisional Application 61783603 · Mar 14, 2013
Provisional Application 61638073 · Apr 25, 2012
Related Publication 20190224126A1 · Jul 25, 2019